Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

doi:10.1007/s13238-017-0500-9

Protein Cell

2018, Vol. 9

Issue (9) : 770-784 https://doi.org/10.1007/s13238-017-0500-9

RESEARCH ARTICLE

Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway

Li Yang, Jing Chen, Xiaoyan Han, Enfan Zhang, Xi Huang, Xing Guo, Qingxiao Chen, Wenjun Wu, Gaofeng Zheng, Donghua He, Yi Zhao, Yang Yang, Jingsong He, Zhen Cai(

)

Multiple Myeloma Treatment Center & Bone Marrow Transplantation Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, China

Download: PDF(3154 KB)
Export: BibTeX | EndNote | Reference Manager | ProCite | RefWorks

Abstract

Clinical success of the proteasome inhibitor established bortezomib as one of the most effective drugs in treatment of multiple myeloma (MM). While survival benefit of bortezomib generated new treatment strategies, the primary and secondary resistance of MM cells to bortezomib remains a clinical concern. This study aimed to highlight the role of p53-induced RING-H2 (Pirh2) in the acquisition of bortezomib resistance in MM and to clarify the function and mechanism of action of Pirh2 in MM cell growth and resistance, thereby providing the basis for new therapeutic targets for MM. The proteasome inhibitor bortezomib has been established as one of the most effective drugs for treating MM. We demonstrated that bortezomib resistance in MM cells resulted from a reduction in Pirh2 protein levels. Pirh2 overexpression overcame bortezomib resistance and restored the sensitivity of myeloma cells to bortezomib, while a reduction in Pirh2 levels was correlated with bortezomib resistance. The levels of nuclear factorkappaB (NF-κB) p65, pp65, pIKBa, and IKKa were higher in bortezomib-resistant cells than those in parental cells. Pirh2 overexpression reduced the levels of pIKBa and IKKa, while the knockdown of Pirh2 via short hairpin RNAs increased the expression of NF-κB p65, pIKBa, and IKKa. Therefore, Pirh2 suppressed the canonical NF-κB signaling pathway by inhibiting the phosphorylation and subsequent degradation of IKBa to overcome acquired bortezomib resistance in MM cells.

Keywords bortezomib drug resistance multiple myeloma NF-κB Pirh2

Corresponding Author(s): Zhen Cai

Issue Date: 21 September 2018

Cite this article:

Li Yang,Jing Chen,Xiaoyan Han, et al. Pirh2 mediates the sensitivity of myeloma cells to bortezomib via canonical NF-κB signaling pathway[J]. Protein Cell, 2018, 9(9): 770-784.

URL:

https://academic.hep.com.cn/pac/EN/10.1007/s13238-017-0500-9
https://academic.hep.com.cn/pac/EN/Y2018/V9/I9/770

1	Bielskiene K, Bagdoniene L, Mozuraitiene J,Kazbariene B, Janulionis E (2015) E3 ubiquitin ligases as drug targets and prognostic biomarkers in melanoma. Medicina (Kaunas) 51:1–9 https://doi.org/10.1016/j.medici.2015.01.007
2	Brinkmann K, Schell M, Hoppe T, Kashkar H (2015) Regulation of the DNA damage response by ubiquitin conjugation. Front Genet 6:98 https://doi.org/10.3389/fgene.2015.00098
3	Cao B, Mao X (2011) The ubiquitin-proteasomal system is critical for multiple myeloma: implications in drug discovery. Am J Blood Res 1:46–56
4	Chao A, Wang TH (2016) Molecular mechanisms for synergistic effect of proteasome inhibitors with platinum-based therapy in solid tumors. Taiwan J Obstet Gynecol 55:3–8 https://doi.org/10.1016/j.tjog.2015.12.004
5	Chauhan D, Tian Z, Nicholson B, Kumar KG, Zhou B, Carrasco R, McDermott JL, Leach CA, Fulcinniti M, Kodrasov MPet al. (2012) A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance. Cancer Cell 22:345–358 https://doi.org/10.1016/j.ccr.2012.08.007
6	Daks A, Petukhov A, Fedorova O, Shuvalov O, Merkulov V, Vasileva E, Antonov A, Barlev NA (2016) E3 ubiquitin ligase Pirh2 enhances tumorigenic properties of human non-small cell lung carcinoma cells. Genes Cancer 7:383–393
7	Gandhi AK, Kang J, Havens CG, Conklin T, Ning Y, Wu L, Ito T, Ando H, Waldman MF, Thakurta Aet al. (2014) Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.). Br J Haematol 164:811–821 https://doi.org/10.1111/bjh.12708
8	Goka ET, Lippman ME (2015) Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression. Oncogene 34:5395–5405 https://doi.org/10.1038/onc.2014.468
9	Hakem A, Bohgaki M, Lemmers B, Tai E, Salmena L, Matysiak-Zablocki E, Jung YS, Karaskova J, Kaustov L, Duan Set al. (2011) Role of Pirh2 in mediating the regulation of p53 and c-Myc. PLoS Genet 7:e1002360 https://doi.org/10.1371/journal.pgen.1002360
10	Halaby MJ, Hakem R, Hakem A (2013) Pirh2: an E3 ligase with central roles in the regulation of cell cycle, DNA damage response, and differentiation. Cell Cycle 12:2733–2737 https://doi.org/10.4161/cc.25785
11	Hao Z, Huang S (2015) E3 ubiquitin ligase Skp2 as an attractive target in cancer therapy. Front Biosci (Landmark Ed) 20:474–490 https://doi.org/10.2741/4320
12	Hou YC, Deng JY (2015) Role of E3 ubiquitin ligases in gastric cancer. World J Gastroenterol 21:786–793 https://doi.org/10.3748/wjg.v21.i3.786
13	Hsieh SC, Kuo SN, Zheng YH, Tsai MH, Lin YS, Lin JH (2013) The E3 ubiquitin ligase SIAH2 is a prosurvival factor overexpressed in oral cancer. Anticancer Res 33:4965–4973
14	Huang YH, Li SC, Huang LH, Chen PC, Lin YY, Lin CC, Kuo HC (2017) Identifying genetic hypomethylation and upregulation of toll-like receptors in Kawasaki disease. Oncotarget. 8(7):11249 https://doi.org/10.18632/oncotarget.14497
15	Jones RJ, Bjorklund CC, Baladandayuthapani V, Kuhn DJ, Orlowski RZ (2012) Drug resistance to inhibitors of the human double minute-2 E3 ligase is mediated by point mutations of p53, but can be overcome with the p53 targeting agent RITA. Mol Cancer Ther 11:2243–2253 https://doi.org/10.1158/1535-7163.MCT-12-0135
16	Jung YS, Qian Y, Chen X (2012) Pirh2 RING-finger E3 ubiquitin ligase: its role in tumorigenesis and cancer therapy. FEBS Lett 586:1397–1402 https://doi.org/10.1016/j.febslet.2012.03.052
17	Kumar S, Rajkumar SV (2008) Many facets of bortezomib resistance/susceptibility. Blood 112:2177–2178 https://doi.org/10.1182/blood-2008-07-167767
18	Landis-Piwowar KR (2012) Proteasome inhibitors in cancer therapy: a novel approach to a ubiquitous problem. Clin Lab Sci 25:38–44
19	Liu J, Shaik S, Dai X, Wu Q, Zhou X, Wang Z, Wei W (2014) Targeting the ubiquitin pathway for cancer treatment. Biochim Biophys Acta 1855:50–60
20	Lou Z, Wang S (2014) E3 ubiquitin ligases and human papillomavirus-induced carcinogenesis. J Int Med Res 42:247–260 https://doi.org/10.1177/0300060513506655
21	Lu G, Middleton RE, Sun H, Naniong M, Ott CJ, Mitsiades CS, Wong KK, Bradner JE, Kaelin WG Jr (2014) The myeloma drug lenalidomide promotes the cereblon-dependent destruction of Ikaros proteins. Science 343:305–309 https://doi.org/10.1126/science.1244917
22	Lub S, Maes K, Menu E, De Bruyne E, Vanderkerken K, Van Valckenborgh E (2016) Novel strategies to target the ubiquitin proteasome system in multiple myeloma. Oncotarget 7:6521–6537 https://doi.org/10.18632/oncotarget.6658
23	Malard F, Harousseau JL, Mohty M (2017) Multiple myeloma treatment at relapse after autologous stem cell transplantation: a practical analysis. Cancer Treat Rev 52:41–47 https://doi.org/10.1016/j.ctrv.2016.11.005
24	Malek E, Abdel-Malek MA, Jagannathan S, Vad N, Karns R, Jegga AG, Broyl A, van Duin M, Sonneveld P, Cottini Fet al. (2016) Pharmacogenomics and chemical library screens reveal a novel SCFSKP2 inhibitor that overcomes Bortezomib resistance in multiple myeloma. Leukemia. 31(3):645–653 https://doi.org/10.1038/leu.2016.258
25	Masumoto K, Kitagawa M (2016) E3 ubiquitin ligases as molecular targets in human oral cancers. Curr Cancer Drug Targets 16:130–135 https://doi.org/10.2174/1568009616666151112122336
26	Micel LN, Tentler JJ, Smith PG, Eckhardt GS (2013) Role of ubiquitin ligases and the proteasome in oncogenesis: novel targets for anticancer therapies. J Clin Oncol 31:1231–1238 https://doi.org/10.1200/JCO.2012.44.0958
27	Nelson JK, Cook EC, Loregger A, Hoeksema MA, Scheij S, Kovacevic I, Hordijk PL, Ovaa H, Zelcer N (2016) Deubiquitylase inhibition reveals liver X receptor-independent transcriptional regulation of the E3 Ubiquitin Ligase IDOL and lipoprotein uptake. J Biol Chem 291:4813–4825 https://doi.org/10.1074/jbc.M115.698688
28	Niewerth D, Jansen G, Assaraf YG, Zweegman S, Kaspers GJ, Cloos J (2015) Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Resist Updat 18:18–35 https://doi.org/10.1016/j.drup.2014.12.001
29	Ooi MG, Hayden PJ, Kotoula V, McMillin DW, Charalambous E, Daskalaki E, Raje NS, Munshi NC, Chauhan D, Hideshima Tet al. (2009) Interactions of the Hdm2/p53 and proteasome pathways may enhance the antitumor activity of bortezomib. Clin Cancer Res 15:7153–7160 https://doi.org/10.1158/1078-0432.CCR-09-1071
30	Petzold G, Fischer ES, Thoma NH (2016) Structural basis of lenalidomide-induced CK1alpha degradation by the CRL4 ubiquitin ligase. Nature 532(7597):127–130 https://doi.org/10.1038/nature16979
31	Rajkumar SV (2016) Myeloma today: disease definitions and treatment advances. Am J Hematol 91:90–100 https://doi.org/10.1002/ajh.24236
32	Raninga PV, Di Trapani G, Vuckovic S, Tonissen KF (2016) TrxR1 inhibition overcomes both hypoxia-induced and acquired bortezomib resistance in multiple myeloma through NF-small ka, Cyrillicbeta inhibition. Cell Cycle 15:559–572 https://doi.org/10.1080/15384101.2015.1136038
33	Severe N, Dieudonne FX, Marie PJ (2013) E3 ubiquitin ligasemediated regulation of bone formation and tumorigenesis. Cell Death Dis 4:e463 https://doi.org/10.1038/cddis.2012.217
34	Sharma P, Nag A (2014) CUL4A ubiquitin ligase: a promising drug target for cancer and other human diseases. Open Biol 4:130217 https://doi.org/10.1098/rsob.130217
35	Sun RC, Denko NC (2014) Hypoxic regulation of glutamine metabolism through HIF1 and SIAH2 supports lipid synthesis that is necessary for tumor growth. Cell Metab 19:285–292 https://doi.org/10.1016/j.cmet.2013.11.022
36	Tu Y, Chen C, Pan J, Xu J,Zhou ZG, Wang CY (2012) The Ubiquitin Proteasome Pathway (UPP) in the regulation of cell cycle control and DNA damage repair and its implication in tumorigenesis. Int J Clin Exp Pathol 5:726–738
37	Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM (2016) XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IkappaBalpha and overcomes acquired proteasome inhibitor resistance in human multiple myeloma. Oncotarget 7:78896–78909 https://doi.org/10.18632/oncotarget.12969
38	Wang G, Chan CH, Gao Y, Lin HK (2012) Novel roles of Skp2 E3 ligase in cellular senescence, cancer progression, and metastasis. Chin J Cancer 31:169–177 https://doi.org/10.5732/cjc.011.10319
39	Wu B, Chu X, Feng C, Hou J, Fan H, Liu N, Li C, Kong X, Ye X, Meng S (2015) Heat shock protein gp96 decreases p53 stability by regulating Mdm2 E3 ligase activity in liver cancer. Cancer Lett 359:325–334 https://doi.org/10.1016/j.canlet.2015.01.034
40	Yang S, Chen Y, Sun F, Ni Q, Wang H, Huang Y,Zhang C, Liu K, Wang S, Qiu Jet al. (2016) Downregulated PIRH2 can decrease the proliferation of breast cancer cells. Arch Med Res 47:186–195 https://doi.org/10.1016/j.arcmed.2016.06.004
41	Yerlikaya A, Yontem M (2013) The significance of ubiquitin proteasome pathway in cancer development. Recent Pat Anticancer Drug Discov 8:298–309 https://doi.org/10.2174/1574891X113089990033
42	Yin J, Zhu JM, Shen XZ (2015) The role and therapeutic implications of RING-finger E3 ubiquitin ligases in hepatocellular carcinoma. Int J Cancer 136:249–257 https://doi.org/10.1002/ijc.28717
43	Zhang J, Wan L, Dai X, Sun Y, Wei W (2014) Functional characterization of Anaphase Promoting Complex/Cyclosome (APC/C) E3 ubiquitin ligases in tumorigenesis. Biochim Biophys Acta 1845:277–293
44	Zhu R, Xi H, Li YH, Jiang H, Zou JF, Hou J (2009) Establishment of a bortezomib-resistant myeloma cell line and differential proteins analysis by MALDI-OF-MS. Zhejiang Da Xue Xue Bao Yi Xue Ban 38:445–452

[1]	Chen Ling, Zunpeng Liu, Moshi Song, Weiqi Zhang, Si Wang, Xiaoqian Liu, Shuai Ma, Shuhui Sun, Lina Fu, Qun Chu, Juan Carlos Izpisua Belmonte, Zhaoxia Wang, Jing Qu, Yun Yuan, Guang-Hui Liu. Modeling CADASIL vascular pathologies with patient-derived induced pluripotent stem cells[J]. Protein Cell, 2019, 10(4): 249-271.
[2]	Guoxing Zheng, Changying Jiang, Yulin Li, Dandan Yang, Youcai Ma, Bing Zhang, Xuan Li, Pei Zhang, Xiaoyu Hu, Xueqiang Zhao, Jie Du, Xin Lin. TMEM43-S358L mutation enhances NF-κBTGFβ signal cascade in arrhythmogenic right ventricular dysplasia/cardiomyopathy[J]. Protein Cell, 2019, 10(2): 104-119.
[3]	Yu-Shi Wang, He Li, Yang Li, Hongyan Zhu, Ying-Hua Jin. Identification of natural compounds targeting Annexin A2 with an anti-cancer effect[J]. Protein Cell, 2018, 9(6): 568-579.
[4]	Ping Wang, Zunpeng Liu, Xiaoqian Zhang, Jingyi Li, Liang Sun, Zhenyu Ju, Jian Li, Piu Chan, Guang-Hui Liu, Weiqi Zhang, Moshi Song, Jing Qu. CRISPR/Cas9-mediated gene knockout reveals a guardian role of NF-κB/RelA in maintaining the homeostasis of human vascular cells[J]. Protein Cell, 2018, 9(11): 945-965.
[5]	Yingjiao Xue,Shenda Hou,Hongbin Ji,Xiangkun Han. Evolution from genetics to phenotype: reinterpretation of NSCLC plasticity, heterogeneity, and drug resistance[J]. Protein Cell, 2017, 8(3): 178-190.
[6]	Yi Lu, Taijiao Jiang. Pseudovirus-based neuraminidase inhibition assays reveal potential H5N1 drug-resistant mutations[J]. Prot Cell, 2013, 4(5): 356-363.
[7]	Yu Guo, Jing Wang, Guojun Niu, Wenqing Shui, Yuna Sun, Honggang Zhou, Yaozhou Zhang, Cheng Yang, Zhiyong Lou, Zihe Rao. A structural view of the antibiotic degradation enzyme NDM-1 from a superbug[J]. Prot Cell, 2011, 2(5): 384-394.

Viewed

Full text

Abstract

Cited

Shared

Discussed